Author details

Full Name

Jonathan W Simons

Affiliation

ORCID

Career Start Year

1986

Papers

112

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
34446369	Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel.	Eur Urol Oncol	2022
33596212	Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer.	PLoS One	2021
33576154	Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.	Mol Oncol	2021
32908352	Prostate Cancer Foundation-Department of Veterans Affairs Partnership: A Model of Public-Private Collaboration to Advance Treatment and Care of Invasive Cancers.		2020
34258585	Accelerating precision medicine in metastatic prostate cancer.	Nat Cancer	2020
30381857	Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting.	Prostate	2019
29401003	Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?	J Clin Oncol	2018
27679977	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.	Prostate	2017
28925066	Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.	Prostate	2017
26477609	Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.	Prostate	2016
26888795	Oslerian Genomics for Prostate Cancer Oncology.	Oncology	2016
27272144	The 22nd annual prostate cancer foundation scientific retreat report.	Prostate	2016
25893521	The 21st Annual Prostate Cancer Foundation Scientific Retreat report.	Prostate	2015
25358693	Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.	Prostate	2015
24668884	Enzyme 15-lipoxygenase 1 promotes hypoxia-inducible factor 1Î± turnover and reduces vascular endothelial growth factor expression: implications for angiogenesis.	Cancer Medicine	2014
25367978	Prostate cancer immunotherapy: beyond immunity to curability.	Cancer Immunology Research	2014
24249419	Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting.	Prostate	2014
24719035	The 20th Annual Prostate Cancer Foundation Scientific Retreat report.	Prostate	2014
23536559	The 19th annual Prostate Cancer Foundation scientific retreat.	Cancer Res	2013
24135135	Tracking the clonal origin of lethal prostate cancer.	J Clin Invest	2013
21394742	The 17th Annual Prostate Cancer Foundation scientific retreat: meeting report.	Prostate	2011
21307934	The genomic complexity of primary human prostate cancer.	Nature	2011
20166134	The Prostate Cancer Foundation 16th Annual Scientific Retreat: meeting report.	Prostate	2010
19251694	SEPT9_v1 up-regulates hypoxia-inducible factor 1 by preventing its RACK1-mediated degradation.	Journal of Biological Chemistry	2009
18213636	The current state of preclinical prostate cancer animal models.	Prostate	2008
18381457	Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells.	Cancer Res	2008
18190836	Quantum dots: emerging applications in urologic oncology.	Urologic Oncology: Seminars and Original Investigations	2008
18646045	Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer.	Cancer	2008
17439359	Nanotechnology applications in cancer.	Annual Review of Biomedical Engineering	2007
17606721	Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.	Clin Cancer Res	2007
17555393	Nanotechnology for targeted cancer therapy.	Expert Rev Anticancer Ther	2007
17546006	Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry.	Nat Protoc	2007
16424018	MSF-A interacts with hypoxia-inducible factor-1alpha and augments hypoxia-inducible factor transcriptional activation to affect tumorigenicity and angiogenesis.	Cancer Research	2006
16184550	KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line.	International Journal of Cancer	2006
17178898	Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model.	Cancer Res	2006
16962494	Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.	Urologic Oncology: Seminars and Original Investigations	2006
16954428	Hypoxia-inducible factor-1 in human breast and prostate cancer.	Endocrine-Related Cancer	2006
16740763	Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naÃ¯ve prostate cancer.	Clin Cancer Res	2006
16223724	Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells.	Journal of Biological Chemistry	2005
15735697	Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells.	Oncogene	2005
15722017	In vivo molecular and cellular imaging with quantum dots.	Current Opinion in Biotechnology	2005
15068831	Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis.		2004
15382039	NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms.	International Journal of Cancer	2004
15137054	HIF at the crossroads between ischemia and carcinogenesis.	Journal of Cellular Physiology	2004
15197342	Exploitation of the HIF axis for cancer therapy.	Cancer Biology and Therapy	2004
15126380	Proceedings of the Oxygen Homeostasis/Hypoxia Meeting.	Cancer Res	2004
15124131	Novel therapeutic strategies for androgen-independent prostate cancer: an update.	Seminars in Oncology	2004
12646199	Dibenzoylmethane, a natural dietary compound, induces HIF-1 alpha and increases expression of VEGF.	Biochemical and Biophysical Research Communications	2003
12504055	Dosimetric and technical considerations for interstitial adenoviral gene therapy as applied to prostate cancer.	Int J Radiat Oncol Biol Phys	2003
12869212	Replicative oncolytic adenoviruses in multimodal cancer regimens.	Hum Gene Ther	2003